BTI BiOasis Technologies Inc

biOasis Technologies Inc. (TSX VENTURE:BTI) is pleased to announce that
preclinical data on its proprietary BT2111 program will be presented during the
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
Therapeutics being held in Boston, MA from October 19-23, 2013. 


biOasis' presentation entitled "BT2111, a new anticancer agent composed of
trastuzumab and Transcend a vector for brain delivery for the treatment of
metastatic HER2+ breast cancer", will be presented on Sunday October 20th, 2013.
The presentation will be held in exhibit hall C-D at 12:30PM under Session
Title: Therapeutic Agents: Biological. 


For more information on the conference please visit www.aacr.org/targetsconference 

ABOUT TRANSCEND & BT2111

biOasis' Transcend is a proprietary platform of carrier proteins capable of
transporting therapeutics and other agents across the blood-brain barrier.
BT2111 is a hybrid drug candidate consisting of a biOasis' Transcend delivery
vector linked to trastuzumab, a humanized monoclonal antibody used clinically in
the treatment of HER2+ breast cancer. It is reported that up to 30% of HER2+
breast cancer patients develop brain metastasis for which therapeutic options
are limited. Because of its ability to cross the blood-brain barrier, biOasis is
developing BT2111 as a potential treatment for brain metastases of HER2+ breast
cancer.  


ABOUT BIOASIS

biOasis Technologies Inc. is a biopharmaceutical company headquartered in
Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery
platform, the Company is focused on creating new drugs that can cross the
blood-brain barrier to address unmet medical needs in the treatment of brain
diseases such as neurodegeneration, metastatic cancer and metabolic diseases.
biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more
information about the Company please visit www.bioasis.ca.


Forward-Looking Statements

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments express or implied by such forward-looking
statements or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining regulatory
approval to market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects for negotiating
additional corporate collaborations or licensing arrangements and their timing.
Specifically, certain risks and uncertainties that could cause such actual
events or results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results expressed or
implied by such statements and information include, but are not limited to, the
risks and uncertainties that: we may not be able to successfully develop and
obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's,
or future products in our targeted corporate objectives; our future operating
results are uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing additional
corporate collaborations or licensing arrangements; we may not be able to
establish marketing and the costs of launching our products may be greater than
anticipated; we have no experience in commercial manufacturing; we may face
unknown risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and other factors
as described in detail in our filings with the Canadian securities regulatory
authorities at www.sedar.com. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward- looking statements and information to reflect subsequent events or
circumstances, except as required by law.


On Behalf of the Board of Directors

Rob Hutchison Chairman & CEO 

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release"


FOR FURTHER INFORMATION PLEASE CONTACT: 
biOasis Technologies Inc.
Rob Hutchison
Chairman & CEO
(778).383.3280
rob@bioasis.ca
www.bioasis.ca

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Giu 2023 a Giu 2024